Network meta-analysis
Body weight change in kilograms (diabetes)
Type 2 diabetes (adults); background therapy: one or more non insulin glucose lowering drugs
weeks 20 to 36 (target week 26)Hypothetical (as if everyone stayed on treatment)Doses of a drug pooledMean difference
18
Randomized trials
11
Treatments
10,200
Participants
39
Trial arms
In plain language
Across 18 trials with 10,200 participants, 7 of 10 treatments had a clearly better result than placebo on body weight change in kilograms (diabetes), and for 3 the evidence could not tell them apart from placebo. The most favorable estimate was for Tirzepatide injection: mean difference -5.13 kg (95% credible interval -7.19 to -3.14).
Lower values favor the treatment. "Clearly" means the 95% credible interval excludes no difference. These are averages across trials; they do not say how any one person will respond. Not medical advice.
Network of trials
Each circle is a treatment; each line joins treatments that were randomized against each other in at least one trial.
Effects compared with Placebo
Mean difference in kg. Lower values favor the treatment.
| Treatment | Bayesian MD (95% CrI) | 95% prediction interval | Frequentist MD (95% CI) | Verdict |
|---|---|---|---|---|
| Tirzepatide injection TIRZ_SC | -5.13 (-7.19 to -3.14) | -7.72 to -2.57 | -5.16 (-7.06 to -3.26) | Better |
| Semaglutide injection SEMA_SC | -3.85 (-5.19 to -2.49) | -5.94 to -1.71 | -3.84 (-5.02 to -2.67) | Better |
| Semaglutide tablet SEMA_PO | -2.91 (-4.02 to -1.87) | -4.88 to -0.99 | -2.91 (-3.85 to -1.98) | Better |
| Liraglutide injection LIRA_SC | -2.09 (-3.22 to -0.99) | -4.02 to -0.14 | -2.09 (-3.06 to -1.12) | Better |
| Exenatide injection EXEN_SC | -2.04 (-3.65 to -0.50) | -4.32 to 0.16 | -2.06 (-3.43 to -0.69) | Better |
| Lixisenatide injection LIXI_SC | -1.39 (-2.66 to -0.17) | -3.44 to 0.65 | -1.40 (-2.45 to -0.34) | Better |
| Dulaglutide injection DULA_SC | -1.19 (-2.03 to -0.41) | -3.04 to 0.58 | -1.19 (-1.90 to -0.47) | Better |
| Sitagliptin SITAGLIPTIN | -0.68 (-1.82 to 0.42) | -2.64 to 1.29 | -0.67 (-1.63 to 0.29) | Unclear |
| Insulin glargine with lixisenatide injection IGLARLIXI_SC | 0.13 (-1.48 to 1.66) | -2.11 to 2.32 | 0.12 (-1.24 to 1.47) | Unclear |
| Insulin glargine INS_GLARGINE | 1.07 (-0.24 to 2.33) | -0.98 to 3.11 | 1.06 (-0.05 to 2.17) | Unclear |
Ranking
How likely each treatment is to be among the best. Rankings ignore the size of differences and their certainty, so read them with the effects above.
League table
Every treatment against every other: mean difference of the row treatment versus the column treatment, posterior median and 95% credible interval. Green: row clearly better; red: row clearly worse.
| Row versus column | PLACEBO | TIRZ_SC | SEMA_SC | SEMA_PO | LIRA_SC | EXEN_SC | LIXI_SC | DULA_SC | SITAGLIPTIN | IGLARLIXI_SC | INS_GLARGINE |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PLACEBO | PLACEBO | 5.13 3.14 to 7.19 | 3.85 2.49 to 5.19 | 2.91 1.87 to 4.02 | 2.09 0.99 to 3.22 | 2.04 0.50 to 3.65 | 1.39 0.17 to 2.66 | 1.19 0.41 to 2.03 | 0.68 -0.42 to 1.82 | -0.13 -1.66 to 1.48 | -1.07 -2.33 to 0.24 |
| TIRZ_SC | -5.13 -7.19 to -3.14 | TIRZ_SC | -1.30 -3.68 to 1.06 | -2.21 -4.46 to -0.01 | -3.04 -5.28 to -0.84 | -3.07 -5.54 to -0.65 | -3.73 -6.10 to -1.44 | -3.94 -5.98 to -1.94 | -4.45 -6.73 to -2.24 | -5.26 -7.69 to -2.74 | -6.19 -8.51 to -3.96 |
| SEMA_SC | -3.85 -5.19 to -2.49 | 1.30 -1.06 to 3.68 | SEMA_SC | -0.94 -2.36 to 0.53 | -1.76 -3.33 to -0.17 | -1.80 -3.77 to 0.24 | -2.46 -4.09 to -0.76 | -2.65 -4.10 to -1.15 | -3.17 -4.50 to -1.90 | -3.98 -5.89 to -1.94 | -4.91 -6.62 to -3.18 |
| SEMA_PO | -2.91 -4.02 to -1.87 | 2.21 0.01 to 4.46 | 0.94 -0.53 to 2.36 | SEMA_PO | -0.82 -1.98 to 0.32 | -0.87 -2.62 to 0.92 | -1.53 -2.90 to -0.13 | -1.72 -2.81 to -0.64 | -2.23 -3.19 to -1.29 | -3.05 -4.68 to -1.31 | -3.98 -5.46 to -2.53 |
| LIRA_SC | -2.09 -3.22 to -0.99 | 3.04 0.84 to 5.28 | 1.76 0.17 to 3.33 | 0.82 -0.32 to 1.98 | LIRA_SC | -0.05 -1.82 to 1.77 | -0.70 -2.18 to 0.78 | -0.89 -2.01 to 0.25 | -1.42 -2.58 to -0.24 | -2.22 -3.89 to -0.40 | -3.15 -4.63 to -1.63 |
| EXEN_SC | -2.04 -3.65 to -0.50 | 3.07 0.65 to 5.54 | 1.80 -0.24 to 3.77 | 0.87 -0.92 to 2.62 | 0.05 -1.77 to 1.82 | EXEN_SC | -0.67 -2.58 to 1.26 | -0.86 -2.37 to 0.68 | -1.37 -3.24 to 0.43 | -2.18 -4.29 to -0.03 | -3.11 -4.92 to -1.23 |
| LIXI_SC | -1.39 -2.66 to -0.17 | 3.73 1.44 to 6.10 | 2.46 0.76 to 4.09 | 1.53 0.13 to 2.90 | 0.70 -0.78 to 2.18 | 0.67 -1.26 to 2.58 | LIXI_SC | -0.20 -1.49 to 1.13 | -0.71 -2.04 to 0.56 | -1.51 -2.87 to -0.08 | -2.45 -3.91 to -0.96 |
| DULA_SC | -1.19 -2.03 to -0.41 | 3.94 1.94 to 5.98 | 2.65 1.15 to 4.10 | 1.72 0.64 to 2.81 | 0.89 -0.25 to 2.01 | 0.86 -0.68 to 2.37 | 0.20 -1.13 to 1.49 | DULA_SC | -0.52 -1.69 to 0.66 | -1.32 -2.80 to 0.20 | -2.26 -3.34 to -1.19 |
| SITAGLIPTIN | -0.68 -1.82 to 0.42 | 4.45 2.24 to 6.73 | 3.17 1.90 to 4.50 | 2.23 1.29 to 3.19 | 1.42 0.24 to 2.58 | 1.37 -0.43 to 3.24 | 0.71 -0.56 to 2.04 | 0.52 -0.66 to 1.69 | SITAGLIPTIN | -0.81 -2.38 to 0.86 | -1.74 -3.21 to -0.29 |
| IGLARLIXI_SC | 0.13 -1.48 to 1.66 | 5.26 2.74 to 7.69 | 3.98 1.94 to 5.89 | 3.05 1.31 to 4.68 | 2.22 0.40 to 3.89 | 2.18 0.03 to 4.29 | 1.51 0.08 to 2.87 | 1.32 -0.20 to 2.80 | 0.81 -0.86 to 2.38 | IGLARLIXI_SC | -0.93 -2.37 to 0.46 |
| INS_GLARGINE | 1.07 -0.24 to 2.33 | 6.19 3.96 to 8.51 | 4.91 3.18 to 6.62 | 3.98 2.53 to 5.46 | 3.15 1.63 to 4.63 | 3.11 1.23 to 4.92 | 2.45 0.96 to 3.91 | 2.26 1.19 to 3.34 | 1.74 0.29 to 3.21 | 0.93 -0.46 to 2.37 | INS_GLARGINE |
Heterogeneity, fit and convergence
Bayesian random effects (primary)
Frequentist check (netmeta)
Inconsistency
Do trials comparing two treatments directly agree with the indirect evidence through other treatments?
No comparison here has both direct and indirect evidence, so inconsistency cannot be checked by node splitting; the between designs Q above is the global check.
Small study effects
A comparison adjusted funnel plot: each point is one trial comparison, centered on its own network estimate. Asymmetry can signal that small trials with unfavorable results are missing.
Fewer than ten trial comparisons, too few to judge funnel plot asymmetry.
Baseline characteristics of the trials
The baseline value of each effect modifier or prognostic factor that applies here, per trial: mean or percent over arms, weighted by the number randomized. A note under a value names a stand in (a median for a mean, 100 minus the male share, Asian subgroup rows, an all Asian site list); "not reported" means no source of the trial prints it.
| Trial | Baseline BMI or body weight (kg/m2) effect modifier, prognostic factor; 17 of 18 | Sex (percent female) effect modifier, prognostic factor; 18 of 18 | Background glucose lowering therapy (stratum S0 to S4) effect modifier, prognostic factor; 18 of 18 | Asian ancestry or region (percent Asian) effect modifier, prognostic factor; 16 of 18 | Kidney function (eGFR) (mL/min/1.73 m2) prognostic factor, effect modifier; 6 of 18 | Treatment duration (weeks) effect modifier; 18 of 18 | Lifestyle co-intervention intensity (none standard intensive) effect modifier, prognostic factor; 18 of 18 |
|---|---|---|---|---|---|---|---|
| NCT03131687 S000010 | 32.57 | 46.85 | S1 | 1.66 | 93.19 | 26 | standard |
| PIONEER 4 S000133 | 32.94 | 48 | S1 | 13.4 | 95.8 | 52 | not_reported |
| NCT01476475 S000191 | 32.1 | 48.92 | S1 | 0.62 | not reported | 24 | not_reported |
| PIONEER 10 S000234 | 26.26 | 25.74 | S1 | 100 | 96.57 | 52 | not_reported |
| NCT01584232 S000246 | 26 | 28.51 | S1 | 100 | not reported | 26 | not_reported |
| AWARD-10 S000305 | 32.68 | 49.99 | S1 | not reported | not reported | 24 | not_reported |
| NCT00976937 S000415 | 36.8 | 59.9 100 minus male share | S1 | 0.6 | not reported | 24 | not_reported |
| SUSTAIN 9 S000483 | 31.9 | 41.72 | S1 | 23.51 | 95.2 | 30 | not_reported |
| PIONEER 12 S000522 | 28.58 | 41.7 | S1 | 75.22 | 103.5 | 26 | not_reported |
| AWARD-8 S001068 | 31.2 | 55.86 | S1 | 1.7 | not reported | 24 | not_reported |
| LIRA-SWITCH™ S001119 | 31.95 | 40.5 | S1 | not reported | not reported | 26 | not_reported |
| AWARD-2 S001130 | 31.55 | 48.52 | S1 | 16.91 | not reported | 78 | not_reported |
| AWARD-6 S001184 | 33.56 | 52.09 | S1 | 0.17 | not reported | 26 | not_reported |
| SUSTAIN S001311 | 27.8 | 42.5 | S1 | 85.03 | 109.33 median | 30 | not_reported |
| LIXILAN JP-O1 S002018 | 26.82 | 35.85 | S1 | 100 region: all sites in Asia | not reported | 52 | not_reported |
| AWARD-1 S002153 | 33.16 | 41.51 | S1 | 2.45 | eGFR below 60: 2.8 percent | 52 | not_reported |
| GETGOAL-M S002188 | 32.85 | 58.44 | S1 | 8.2 | not reported | 24 | not_reported |
| PIONEER 3 S002267 | not reported | 47.16 | S1 | 13.14 | not reported | 78 | not_reported |
Comparability of the trials
Checked across designs (the set of treatments each trial compares) for eligibility, outcome definition and assessment, and the baseline factors above. Flags point to possible intransitivity; notes describe variation that is not tied to design.
- FlagBaseline, Baseline BMI or body weight: design means range from 26.3 (DULA_SC vs SEMA_PO) to 36.8 (LIXI_SC vs SITAGLIPTIN) kg/m2; threshold 3
- FlagBaseline, Sex: design means range from 25.7 (DULA_SC vs SEMA_PO) to 59.9 (LIXI_SC vs SITAGLIPTIN) percent female; threshold 15
- FlagBaseline, Asian ancestry or region: design means range from 0.2 (DULA_SC vs LIRA_SC) to 100.0 (DULA_SC vs SEMA_PO) percent Asian; threshold 30
- FlagBaseline, Kidney function (eGFR): not reported by 12 of 18 trials
- FlagBaseline, Kidney function (eGFR): design means range from 93.2 (DULA_SC vs PLACEBO vs TIRZ_SC) to 109.3 (SEMA_SC vs SITAGLIPTIN) mL/min/1.73 m2; threshold 15
- FlagBaseline, Treatment duration: design means range from 24.0 (DULA_SC vs PLACEBO) to 52.0 (DULA_SC vs EXEN_SC vs PLACEBO) weeks; threshold 26
- NoteOutcome assessment, time point: selected time points span 24 to 30 weeks
- NoteOutcome assessment, analysis set: mixed: full_analysis 8, modified_itt 10
- NoteOutcome assessment, definition: mixed: change in HbA1c from baseline 1, change in HbA1c from baseline to week 26, LOCF 1, not stated 16
- NoteOutcome assessment, intercurrent events (discontinuation): mixed: hypothetical 10, not stated 7, treatment_policy 1
- NoteOutcome assessment, intercurrent events (rescue): mixed: hypothetical 16, not stated 2
- NoteRisk of bias, blinding: mixed: double_blind 12, open_label 5, single_blind 1
- NoteData handling, input conversions: arms_combined 9
| Trial | time weeks | analysis set | definition | instrument | adjudicated | proportion method | intercurrent events (discontinuation) | intercurrent events (rescue) | blinding | funding | start year | Eligibility |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03131687 | 26 | modified_itt | not stated | not stated | not stated | not stated | treatment_policy | hypothetical | double_blind | industry | 2017 | age 18 to 75; T2D at least 6 months; HbA1c 7.0 to 10.5%; BMI 23 to 50; diet and exercise or metformin |
| PIONEER 4 | 26 | full_analysis | not stated | not stated | not stated | not stated | hypothetical | hypothetical | double_blind | industry | 2016 | Age 18 or older; T2D on metformin with or without SGLT2i; HbA1c 7.0 to 9.5 percent; eGFR 60 or more |
| NCT01476475 | 24 | modified_itt | not stated | not stated | not stated | not stated | hypothetical | hypothetical | open_label | industry | 2011 | Adults with T2D; HbA1c 7 to 10 percent on metformin at least 1.5 g/day; insulin naive |
| PIONEER 10 | 26 | full_analysis | not stated | not stated | not stated | not stated | hypothetical | hypothetical | single_blind | industry | 2017 | Japanese adults 20 or older; T2D; HbA1c 7.0 to 10.5 percent on one oral glucose lowering drug |
| NCT01584232 | 26 | full_analysis | not stated | not stated | not stated | not stated | not stated | hypothetical | open_label | industry | 2012 | Japanese adults 20 years or older; BMI 18.5 to less than 35 kg/m2; HbA1c 7.0 to 10.0 percent; on sulfonylurea and/or biguanide |
| AWARD-10 | 24 | modified_itt | not stated | not stated | not stated | not stated | not stated | hypothetical | double_blind | industry | 2015 | T2D; HbA1c 7.0 to 9.5 percent; BMI 45 or lower; SGLT2i with or without metformin |
| NCT00976937 | 24 | modified_itt | not stated | not stated | not stated | not stated | hypothetical | hypothetical | double_blind | industry | 2009 | age 18 to under 50; BMI 30 or more; HbA1c 7.0 to 10 percent; metformin at least 1.5 g/day |
| SUSTAIN 9 | 30 | full_analysis | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2017 | adults 18 or older (20 in Japan); HbA1c 7.0 to 10.5 percent; stable SGLT2i with or without metformin or SU |
| PIONEER 12 | 26 | full_analysis | not stated | not stated | not stated | not stated | hypothetical | hypothetical | double_blind | industry | 2019 | adults with type 2 diabetes on metformin, HbA1c 7.0 to 10.5 percent |
| AWARD-8 | 24 | modified_itt | not stated | not stated | not stated | not stated | not stated | hypothetical | double_blind | industry | 2013 | age 18 or older; BMI up to 45; HbA1c 7.5 to 9.5 percent on sulfonylurea at least half maximal dose |
| LIRA-SWITCH™ | 26 | full_analysis | not stated | not stated | not stated | not stated | hypothetical | hypothetical | double_blind | industry | 2013 | age 18 or more; HbA1c 7.5 to 9.5 percent; BMI 20 or more; on sitagliptin 100 mg and metformin for 90 days or more |
| AWARD-2 | 26 | modified_itt | not stated | not stated | not stated | not stated | not stated | hypothetical | open_label | industry | 2010 | type 2 diabetes on metformin and glimepiride |
| AWARD-6 | 26 | modified_itt | change in HbA1c from baseline | not stated | not stated | not stated | not stated | not stated | open_label | industry | 2012 | adults; HbA1c 7 to 10 percent; metformin 1500 mg/day or more |
| SUSTAIN | 30 | full_analysis | not stated | not stated | not stated | not stated | hypothetical | hypothetical | double_blind | industry | 2017 | Adults 18 or older, HbA1c 7.0 to 10.5 percent on metformin monotherapy, eGFR 60 or more |
| LIXILAN JP-O1 | 26 | modified_itt | change in HbA1c from baseline to week 26, LOCF | not stated | not stated | not stated | hypothetical | hypothetical | open_label | industry | 2016 | insulin naive Japanese adults; HbA1c 7.5 to 10%; FPG 13.8 mmol/L or less; one or two OADs |
| AWARD-1 | 26 | modified_itt | not stated | not stated | not stated | not stated | not stated | hypothetical | double_blind | industry | 2010 | adults with type 2 diabetes on metformin and pioglitazone |
| GETGOAL-M | 24 | modified_itt | not stated | not stated | not stated | not stated | hypothetical | hypothetical | double_blind | industry | 2008 | type 2 diabetes on metformin 1.5 g/day or more for 3 months; HbA1c 7 to 10 percent; FPG 13.9 mmol/L or less |
| PIONEER 3 | 26 | full_analysis | not stated | not stated | not stated | not stated | hypothetical | hypothetical | double_blind | industry | 2016 | adults with T2D; HbA1c 7.0 to 10.5 percent; metformin with or without sulfonylurea |
Trial data
What each trial contributes. Arm rows give the arm value with its standard error, or events over participants; contrast rows give the mean difference on the analysis scale against the trial's first row. Flags mark converted, combined or approximated inputs.
| Trial | Arm | Treatment | Week | Data | Value | SE | Events / N | Flags | Source |
|---|---|---|---|---|---|---|---|---|---|
| NCT03131687 | A1 | PLACEBO | 26 | arm, change | -0.400 | 0.810 | 41 | R0016215:Supplement Table 1 | |
| NCT03131687 | A2+A3+A4+A5 | TIRZ_SC | 26 | arm, change | -6.130 | 0.498 | 171 | arms_combined | R0016215:Supplement Table 1 |
| NCT03131687 | A6 | DULA_SC | 26 | arm, change | -2.700 | 0.780 | 47 | R0016215:Supplement Table 1 | |
| PIONEER 4 | A1 | SEMA_PO | 26 | arm, change | -4.700 | 0.255 | 285 | registry:outcomes | |
| PIONEER 4 | A2 | LIRA_SC | 26 | arm, change | -3.300 | 0.220 | 284 | registry:outcomes | |
| PIONEER 4 | A3 | PLACEBO | 26 | arm, change | -0.700 | 0.260 | 142 | registry:outcomes | |
| NCT01476475 | A1 | IGLARLIXI_SC | 24 | arm, change | -0.970 | 0.289 | 159 | registry:outcomes | |
| NCT01476475 | A2 | INS_GLARGINE | 24 | arm, change | 0.480 | 0.282 | 160 | registry:outcomes | |
| PIONEER 10 | A1+A2+A3 | SEMA_PO | 26 | arm, change | -1.182 | 0.124 | 370 | arms_combined | R0018421:Figure 3D |
| PIONEER 10 | A4 | DULA_SC | 26 | arm, change | 0.300 | 0.300 | 64 | R0018421:Figure 3D | |
| NCT01584232 | A1 | DULA_SC | 26 | arm, change | -0.480 | 0.170 | 180 | R0016159:Table 2 | |
| NCT01584232 | A2 | INS_GLARGINE | 26 | arm, change | 0.940 | 0.170 | 180 | R0016159:Table 2 | |
| AWARD-10 | A1+A2 | DULA_SC | 24 | arm, change | -2.851 | 0.212 | 283 | arms_combined | registry:outcomes |
| AWARD-10 | A3 | PLACEBO | 24 | arm, change | -2.300 | 0.310 | 140 | registry:outcomes | |
| NCT00976937 | A1 | LIXI_SC | 24 | arm, change | -2.510 | 0.294 | 152 | registry:outcomes | |
| NCT00976937 | A2 | SITAGLIPTIN | 24 | arm, change | -1.170 | 0.304 | 160 | registry:outcomes | |
| SUSTAIN 9 | A1 | SEMA_SC | 30 | contrast, md | -3.810 | 0.452 | R0021710:Figure 3b | ||
| SUSTAIN 9 | A2 | PLACEBO | 30 | contrast, md | R0021710:Figure 3b | ||||
| PIONEER 12 | A1+A2+A3 | SEMA_PO | 26 | arm, change | -2.674 | 0.113 | 941 | arms_combined | registry:outcomes |
| PIONEER 12 | A4 | SITAGLIPTIN | 26 | arm, change | -0.500 | 0.142 | 335 | registry:outcomes | |
| AWARD-8 | A1 | DULA_SC | 24 | arm, change | -0.910 | 0.210 | 212 | R0016038:Results | |
| AWARD-8 | A2 | PLACEBO | 24 | arm, change | -0.240 | 0.400 | 53 | R0016038:Results | |
| LIRA-SWITCH™ | A1 | LIRA_SC | 26 | contrast, md | -1.670 | 0.344 | R0025720:Results | ||
| LIRA-SWITCH™ | A2 | SITAGLIPTIN | 26 | contrast, md | R0025720:Results | ||||
| AWARD-2 | A1+A2 | DULA_SC | 26 | arm, change | -1.646 | 0.141 | 542 | arms_combined | registry:outcomes |
| AWARD-2 | A3 | INS_GLARGINE | 26 | arm, change | 1.010 | 0.200 | 259 | registry:outcomes | |
| AWARD-6 | A1 | DULA_SC | 26 | arm, change | -2.900 | 0.220 | 299 | registry:outcomes | |
| AWARD-6 | A2 | LIRA_SC | 26 | arm, change | -3.610 | 0.220 | 299 | registry:outcomes | |
| SUSTAIN | A1+A2 | SEMA_SC | 30 | arm, change | -3.601 | 0.174 | 477 | arms_combined | registry:outcomes |
| SUSTAIN | A3 | SITAGLIPTIN | 30 | arm, change | -0.400 | 0.157 | 253 | registry:outcomes | |
| LIXILAN JP-O1 | A1 | IGLARLIXI_SC | 26 | arm, change | 0.620 | 0.177 | 161 | R0015751:Table 2 | |
| LIXILAN JP-O1 | A2 | LIXI_SC | 26 | arm, change | -1.320 | 0.180 | 157 | R0015751:Table 2 | |
| AWARD-1 | A1+A2 | DULA_SC | 26 | arm, change | -0.589 | 0.180 | 512 | arms_combined | registry:outcomes |
| AWARD-1 | A3 | EXEN_SC | 26 | arm, change | -1.140 | 0.260 | 245 | registry:outcomes | |
| AWARD-1 | A4 | PLACEBO | 26 | arm, change | 1.370 | 0.370 | 109 | registry:outcomes | |
| GETGOAL-M | A1+A2 | LIXI_SC | 24 | arm, change | -2.000 | 0.166 | 497 | arms_combined | R0025872:Results |
| GETGOAL-M | A3 | PLACEBO | 24 | arm, change | -1.600 | 0.270 | 168 | R0025872:Results | |
| PIONEER 3 | A1+A2+A3 | SEMA_PO | 26 | arm, change | -2.199 | 0.102 | 1,396 | arms_combined | registry:outcomes |
| PIONEER 3 | A4 | SITAGLIPTIN | 26 | arm, change | -0.600 | 0.148 | 467 | registry:outcomes |
Rerun this analysis yourself
Remove treatments or trials and refit the frequentist and Bayesian models in your browser, with the same methods as the published analysis.